A Phase I, Open-Label Study to Assess the Pharmacokinetics and Safety of Atezolizumab Administered Intravenously as a Single Agent to Chinese Patients With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase I, Open-Label Study to Assess the Pharmacokinetics and Safety of Atezolizumab Administered Intravenously as a Single Agent to Chinese Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms IMYO29233
  • Sponsors Roche
  • Most Recent Events

    • 01 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 15 Jul 2016 New trial record
    • 08 Jul 2016 Planned initiation date changed from 1 July 2018 to 1 August 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top